Meeting
2017 ASCO Annual Meeting
A phase I study of the safety and immunogenicity of a multipeptide personalized genomic vaccine in the adjuvant treatment of solid cancers.
Authors
Chrisann Kyi
Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY
Chrisann Kyi , Rachel Lubong Sabado , Ana Blazquez , Marshall R. Posner , Eric Michael Genden , Brett A. Miles , Hooman Khorasani , Peter Remsen Dottino , Hanna Irie , Elisa R. Port , Andrea S Wolf , Hearn J. Cho , Samir S. Parekh , John Mandeli , Matthew Galsky , William K. Oh , Sacha Gnjatic , Eric E. Schadt , Philip Adam Friedlander , Nina Bhardwaj
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Therapeutics—Immunotherapy
Track
Developmental Therapeutics and Translational Research,Immunotherapy
Sub Track
Vaccines
Clinical Trial Registration Number
NCT02721043
Citation
J Clin Oncol 35, 2017 (suppl; abstr TPS3114)
DOI
10.1200/JCO.2017.35.15_suppl.TPS3114
Abstract #
TPS3114
Poster Bd #
197b
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Breakthrough
The effect of corticosteroid on immunogenicity of SARS-CoV-2 vaccines in solid cancer patients.
First Author: Chayanee Samdaengpan
Poster
2021 ASCO Annual Meeting
Long term results from a phase 1 trial of GEN-009, a personalized neoantigen vaccine, combined with PD-1 inhibition in advanced solid tumors.
First Author: Maura L. Gillison
Poster
2021 Gastrointestinal Cancers Symposium
A phase I study of safety and immunogenicity of survivin long peptide vaccine (SurVaxM) in patients (pts) with metastatic neuroendocrine tumors (NETs).
First Author: Medhavi Gupta
Poster
2019 ASCO Annual Meeting
Phase I trial of a novel DNA vaccine in patients (pts) with smoldering Waldenstrom macroglobulinemia (sWM).
First Author: Sheeba K. Thomas